Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT/QTc Study of DSP-6952 (minesapride) in Healthy Volunteers
jRCT2080223729Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of minesapride (3 arms), sponsored by Sumitomo Pharma. Primary endpoint: QT/QTc interval change with DSP-6952. Started Nov 2017; status: completed.
02
Drugs
minesapride
Beyond the preview
Go deeper on jRCT2080223729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223729.